Table 2. Change from baseline on questionnaire measures.
|
Control |
Remitted |
|||
|---|---|---|---|---|
| Placebo | Vortioxetine | Placebo | Vortioxetine | |
| State-STAI score | 2.1 (4.2) | −0.2 (4.8) | 0.4 (8.5) | −2.6 (6.6) |
| PANAS-positive score | −0.4 (5.6) | −1.6 (5.5) | −1.5 (5.8) | 2.8 (5.2) |
| PANAS-negative score | 0.08 (1.4) | −0.3 (1.4) | −0.2 (5.0) | −0.5 (2.2) |
| BDI score | 0.42 (2.8) | 0.46 (2.6) | 0.42 (5.3) | −3.08 (5.9) |
| HAM-D17 score | 0.17 (1.1) | 0.67 (1.6) | 0.83 (3.2) | 0.29 (1.7) |
| PDQ total score | −1.92 (5.7) | −5.42 (6.2) | −4.96 (6.6) | −7.58 (8.4) |
Abbreviations: BDI, Beck Depression Inventory; HAM-D17, 17-item Hamilton Depression Rating Scale; PANAS, Positive and Negative Affect Scale; PDQ, Perceived Deficits Questionnaire; STAI, Spielberger State-Trait Anxiety Inventory.
Note scores are calculated as post treatment—baseline; therefore, a reduction in symptoms is shown as a negative number. Data are presented as mean (s.d.).